Researchers examine mutations of the LRRK2 gene and R1441G, known as the Basque mutation, to better understand Parkinson's disease among patients in the Basque Country.
Activating Nrf2 helps with the removal of LRRK2 and alpha synuclein, researchers report.
An experimental small molecule helped restore the removal of mitochondria from dopamine-producing neurons in the brain. The findings may help in the development of new therapies for Parkinson's disease.
A new study reveals a defective version of astrocytes may be linked to the build up of alpha synuclein and could spur Parkinson's disease. The findings show the important role glial cells play in Parkinson's and offers insights into new targets for therapies to fight the neurodegenerative disease.
Researchers have discovered an interaction in neurons that contributes to Parkinson's disease.
Vitamin B12 significantly prevents the neurotoxicity of LRRK2 genetic variants associated with hereditary Parkinson's disease. The findings may help with the development of new therapies to combat the neurodegenerative disease.
Mutations in LRRK2 leads to dysfunctional auxilin and impaired synaptic vesicle endocytosis in Parkinson's patients, researchers report.
Researchers discover how the most common genetic cause of PD kills neurons. The findings could assist in monitoring the disease progression and provide new treatment options.
Researchers have discovered a compound which could counter Parkinson's disease in two ways at once.
A new study reports that a drug currently being used to treat liver disease has shows promise as an effective treatment to slow the progression of Parkinson's disease.
Using stem cells derived from Parkinson's patients, researchers confirm mitochondrial changes.